Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

Transcode Therapeutics, Inc.

CIK 1829635 RNAZ·Pharmaceutical Preparations · All EDGAR filings ↗

Progression

  1. Going concern 10-K
  2. Finance chief departure 8-K +149d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Finance chief departure elevated Filing comparison

Transcode Therapeutics, Inc.'s Chief Financial Officer departed, replaced on an interim basis

Evidence
Interim only
Yes
Item code
5.02
Item title
Departure of Directors or Certain Officers
Role
Chief Financial Officer
Severity
elevated
Source
SEC 8-K item code
Successor named
No
Why
The company's chief financial or accounting officer departed, disclosed under 8-K Item 5.02.

Source filing ↗

Going concern Filing comparison

Transcode Therapeutics, Inc. disclosed substantial doubt about its ability to continue as a going concern

No going-concern disclosure → Substantial doubt about ability to continue as a going concern

Substantial Doubt Regarding Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations, has experienced cash used from operations, and has an accumulated deficit, that raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that…
Evidence
Blank check
No
Comparable
Yes
Current state
substantial_doubt
Current state label
Substantial doubt about ability to continue as a going concern
Direction
escalated
Located in
going-concern note
Prior filed
2025-04-30
Prior form
10-K/A
Prior state
none
Prior state label
No going-concern disclosure
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.

Source filing ↗ Prior filing ↗

Late filing elevated Filing comparison

Transcode Therapeutics, Inc. told the SEC it could not file its annual report on time

TransCode Therapeutics, Inc, (the “Company”) has determined that it will not be able to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, (the “2025 Form 10-K”) within the prescribed time period for such filing without unreasonable effort or expense. On October 8, 2025, the Company entered into a series of related agreements (collectively, the “Agreement”) with DEFJ, LLC (“DEFJ”) pursuant to which the Company (1) purchased all of DEFJ’s membership interests in ABCJ, LLC, a Delaware limited liability company, in exchange for an aggregate of 83,285 shares of the Company’s common stock, par value $0.0001 per share, (the “Common Stock”) and 1,152.9568 shares of…
Evidence
Days past due date
0
Routine
No
Severity
elevated
Source
Form 12b-25 (notification of late filing)
Stated reason
TransCode Therapeutics, Inc, (the “Company”) has determined that it will not be able to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, (the “2025 Form 10-K”) within the prescribed time period for such filing without unreasonable effort or expense. On October 8, 2025, the Company entered into a series of related agreements (collectively, the “Agreement”) with DEFJ, LLC (“DEFJ”) pursuant to which the Company (1) purchased all of DEFJ’s membership interests in ABCJ, LLC, a Delaware limited liability company, in exchange for an aggregate of 83,285 shares of the Company’s common stock, par value $0.0001 per share, (the “Common Stock”) and 1,152.9568 shares of…
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗